KITE Profile
Kite
Pharma, Inc. is a biopharmaceutical company that specializes in the
development and commercialization of cancer immunotherapy products.
The company focuses on developing chimeric antigen receptor (CAR) and
T cell receptor (TCR) engineered cell therapies for the treatment of
cancer. Its lead product candidate is axicabtagene ciloleucel, an
autologous T-cell therapy, which is in Phase II clinical trials for
the treatment of patients with refractory aggressive non-Hodgkin
lymphoma.
Kite Pharma was founded in 2009 and is headquartered
in Santa Monica, California. The company has a strong research and
development team, with a focus on developing novel cell therapies for
the treatment of cancer. The company's approach is based on the use of
genetically engineered T cells, which are designed to target and kill
cancer cells.
Kite Pharma has been recognized for its
innovative approach to cancer immunotherapy and has received
significant funding from the National Cancer Institute, the National
Institutes of Health, and other organizations. The company has also
entered into strategic partnerships with other companies in the
biopharmaceutical industry to accelerate the development and
commercialization of its product candidates.
Kite Pharma has a
strong financial position, with a market capitalization of over $10
billion as of March 2023. The company has reported strong revenue
growth in recent years, driven by the launch of its first product,
Yescarta, which is approved for the treatment of relapsed or
refractory large B-cell lymphoma. Kite Pharma was acquired by Gilead
Sciences in 2017 for $11.9 billion, which has provided the company
with additional resources to support its ongoing research and
developme
|
